Novo Nordisk A / S produces and markets pharmaceutical products and services. Since its founding in Denmark in 1923, the company has developed into a leading company in the diabetes sector worldwide.
According to Novo Nordisk's latest financial reports the company has a price-to-book ratio of 6.72746.
The price-to-book ratio is a way to measure how much the stock market thinks a company is worth compared to how much the company says its assets are worth on paper.
Year | P/B ratio | Change |
---|---|---|
2024-12-31 | 19.2 | -34.36% |
2023-12-31 | 29.2 | 15.38% |
2022-12-31 | 25.3 | 6.95% |
2021-12-31 | 23.7 | 52.01% |
2020-12-31 | 15.6 | -3.3% |
2019-12-31 | 16.1 | 14.45% |
2018-12-31 | 14.1 | -13.79% |
2017-12-31 | 16.3 | 11.13% |
2016-12-31 | 14.7 | -33.6% |
2015-12-31 | 22.1 | 29.3% |
2014-12-31 | 17.1 | 33.29% |
2013-12-31 | 12.8 | 1.69% |
2012-12-31 | 12.6 | 23.48% |
2011-12-31 | 10.2 | -0.13% |
2010-12-31 | 10.2 | 74.1% |
2009-12-31 | 5.88 | 12.05% |
2008-12-31 | 5.25 | -21.13% |
2007-12-31 | 6.65 | 33.99% |
2006-12-31 | 4.97 | 19.09% |
2005-12-31 | 4.17 | 12.43% |
2004-12-31 | 3.71 | 12.2% |
2003-12-31 | 3.31 | 10.19% |
2002-12-31 | 3.00 |